MR-guided delivery of AAV2-BDNF into the entorhinal cortex of non-human primates

Alan H. Nagahara1 · Bayard R. Wilson1 · Iryna Ivasyk1 · Imre Kovacs1 · Saytam Rawalji1 · John R. Bringas2 · Phillip J. Pivirotto2 · Waldy San Sebastian2 · Lluis Samaranch2 · Krystof S. Bankiewicz2 · Mark H. Tuszynski1,3

Received: 25 July 2017 / Revised: 20 December 2017 / Accepted: 12 February 2018 / Published online: 13 March 2018
© Macmillan Publishers Limited, part of Springer Nature 2018

Abstract
Brain-derived neurotrophic factor (BDNF) gene delivery to the entorhinal cortex is a candidate for treatment of Alzheimer’s disease (AD) to reduce neurodegeneration that is associated with memory loss. Accurate targeting of the entorhinal cortex in AD is complex due to the deep and atrophic state of this brain region. Using MRI-guided methods with convection-enhanced delivery, we were able to accurately and consistently target AAV2-BDNF delivery to the entorhinal cortex of non-human primates; 86 ± 3% of transduced cells in the targeted regions co-localized with the neuronal marker NeuN. The volume of AAV2-BDNF (3 × 10^8 vg/µl) infusion linearly correlated with the number of BDNF labeled cells and the volume (mm^3) of BDNF immunoreactivity in the entorhinal cortex. BDNF is normally trafficked to the hippocampus from the entorhinal cortex; in these experiments, we also found that BDNF immunoreactivity was elevated in the hippocampus following therapeutic BDNF vector delivery to the entorhinal cortex, achieving growth factor distribution through key memory circuits. These findings indicate that MRI-guided infusion of AAV2-BDNF to the entorhinal cortex of the non-human primate results in safe and accurate targeting and distribution of BDNF to both the entorhinal cortex and the hippocampus. These methods are adaptable to human clinical trials.

Introduction
Alzheimer’s disease (AD) is the most common neurodegenerative disorder, and lacks effective disease-modifying therapies. The entorhinal cortex is typically the first brain region affected in AD [1–5], and neuronal degeneration in the entorhinal cortex is associated with what is often the first and cardinal symptom of AD, short-term memory loss [6, 7]. Thus, therapeutic strategies to slow entorhinal/hippocampal neuronal degeneration could be of substantial value in the treatment of AD.

Brain-derived neurotrophic factor (BDNF) is the most abundant neurotrophic factor in the adult brain, and its levels decline in the entorhinal cortex in AD [8–10]. Previous studies indicate that therapeutic BDNF delivery to the entorhinal cortex of amyloid mutant mice, aged and lesioned rats, as well as aged and lesioned non-human primates reduces neuronal death, improves synaptic markers, improves molecular signaling, and improves hippocampal-dependent learning and memory [11, 12]. Accordingly, BDNF is a candidate for translational human clinical trials [8].

Central nervous system (CNS) growth factors are medium-sized, moderately charged proteins that do not cross the blood–brain barrier [13]. Hence, they must be administered into the CNS directly to access degenerating neuronal populations [8]. However, when growth factors broadly spread through the CNS, they elicit intolerable adverse effects including weight loss, sensory disturbances, and Schwann cell migration into the CNS [8]. Thus, their testing in clinical trials requires delivery methods that achieve both central and restricted delivery solely to the regions of degenerating neurons. Gene delivery is a potential means of accomplishing this goal. We recently reported that gene
delivery of another growth factor to the basal forebrain region of AD patients, nerve growth factor (NGF), was safe and well tolerated, and elicited classic “trophic” responses from degenerating cholinergic neurons [14]. Yet a 49-patient, double blind, sham surgery-controlled Phase 2 trial did not show efficacy in reducing cognitive decline (https://clinicaltrials.gov/ct2/show/NCT00876863). However, gene delivery was off-target in at least half of the intended sites in these patients based on examination of several brains, despite the use of state-of-the-art clinical stereotaxic methods and planning software (unpublished observations). This highlights the need to utilize more accurate methods for targeting and distributing growth factors in human clinical trials. Image-guided vector delivery is a potential method for achieving this important goal.

The entorhinal cortex is located on the ventromedial surface of the temporal lobe. It is an elongate structure 30 mm in antero-posterior length, 9–18 mm in width (along the cortical surface), and 3 mm thick [15]. Accordingly, accurately targeting this structure, which becomes atrophic in AD [16, 17], is a challenge when using conventional stereotactic approaches.

Recently we developed methods to enhance vector targeting and distribution in intracranial regions using magnetic resonance imaging (MRI)-guided infusions together with co-infusions of the safe MR contrast agent gadoteridol [18–21]. Subjects undergo MRI scans during brain infusions, demonstrating real-time vector infusion and distribution. Combining this approach with convection-enhanced infusion procedures can further optimize vector distribution in the brain [22]. This approach has been implemented in clinical trials for brain tumors [23], growth factor and enzymatic gene therapy for Parkinson’s disease [24], and gene replacement in aromatic acid decarboxylase (AADC) deficient children [25].

We adapted these previously described methods in an effort to accurately target the entorhinal cortex in non-human primates as part of a translational program of adeno-associated virus (serotype2) AAV2-BDNF (AAV2-BDNF) gene therapy for AD. We now report improved targeting and distribution of AAV2-BDNF in the non-human primate brain using MRI-guided convection-enhanced vector delivery with co-infusion of gadoteridol. The distribution of gadoteridol on initial MRI scan correlated highly with actual vector distribution by BDNF immunolabeling of brains. BDNF protein is effectively anterogradely distributed to the hippocampus after entorhinal cortex delivery. Accordingly, these findings support the use of this improved method for therapeutic growth factor gene delivery in upcoming clinical trials of AAV2-BDNF gene delivery in AD.

Results

A total of 18 adult monkeys of both genders underwent infusion of AAV2-BDNF into the entorhinal cortex (detailed in Methods), including five cynomologus macaques and 13 rhesus macaques. An MR-compatible stereotaxic frame was attached to the skull that guided the passage of an MR-compatible infusion needle fabricated from ceramic [26]. Deeply sedated subjects were placed in a 3 Tesla General Electric MR scanner, and needle targeting to the medial entorhinal cortex was assisted by MR guidance (see Methods). The medial entorhinal cortex is located in the most ventral and medial aspect of the frontal lobe (Figs. 1–3). Upon needle positioning, subjects received infusions of AAV2-BDNF (0.3 × 10^{12} vg/ml) mixed with the MR-dense substance, gadoteridol 2 mM. The subjects received 1–3 infusions per side in volumes ranging from 15 to 130 µl/site; a range of volumes and sites was used because we continued infusions until the targeted brain region was filled; for example, if some vector was initially infused into a subcortical white matter region instead of the intended target, the needle was re-positioned and additional vector was infused. There was no effort to infuse a pre-planned volume of vector; instead, we continued infusions until the target brain region received the vector, regardless of total volume infused. After pre-planned survival periods of 1–6 months, the brains were examined for accuracy of BDNF targeting to the entorhinal cortex and cell type infected with AAV2. Vector spread as measured by gadoteridol diffusion was compared to the...
distribution of the intended gene product by tissue labeling using BDNF immunoabeling. We then correlated the total volume of vector infused per site to the volume of brain transduced by BDNF immunolabeling (see Methods).

Targeting the entorhinal cortex

In a monkey, the entorhinal cortex is located, as in the human, in the medial temporal lobe (Fig. 1). This brain region receives inputs from broad regions of the cortex, and in turn directly projects to the dentate gyrus of the hippocampus [27–29]. Outputs from the hippocampus then return to the entorhinal cortex, which sends projections to other cortical regions that are sites of long-term memory storage, as well as the parahippocampus gyrus and perihinal cortex [30, 31]. This neural circuitry is essential for learning and memory [31–33].

In the rhesus monkey, the entorhinal cortex is about 15 mm in total rostral-to-caudal extent, 5–9 mm wide, and 2–3 mm in depth from the cortical surface, with an estimated volume of 255 mm [34]. Grossly, this brain region is located on the ventral most aspect of the medial temporal lobe, and its most ventrolateral component is demarcated by the rhinal fissure (Fig. 2). Its more dorsal extent reaches the amygdala (rostral half) and subicular region (caudal half). Both the rhinal tissue and subicular region can be recognized on MRI scans (Fig. 2). The midpoint of the antero-poster range of the entorhinal cortex (e.g., coordinate 0.75 cm relative to either end of the 1.5 cm length of the entorhinal cortex) is recognizable on MRI scans as the point at which the hippocampus first becomes evident on coronal brain sections. The cortical surface is also visible on MRI scans, and these infusions aim to be centered 1 mm below this surface. Thus, for all three dimensions of the entorhinal cortex, there are fiducial markings that are recognizable on MRI scans: (1) in the antero-posterior plane, the first appearance of the hippocampus on coronal brain sections (1 mm thick slices), (2) in the medio-lateral plane, the shape of the amygdala/subiculum (dorsal) and the rhinal fissure (lateral), and (3) in the ventro-medial plane, the cortical surface (Fig. 2). We used these MRI landmarks to target vector infusions. The animals received from one to three vector infusions per side of the brain. The present study focused on the question of whether we are able to use MRI guidance with gadoteridol infusion to reliably infuse AAV2-BDNF into this small brain region.

MRI-guided infusions enable precise, accurate gene delivery to the entorhinal cortex

The injection needle could be readily visualized on MRI scans of the brain, as expected (Fig. 3a). This allowed confirmation of the accuracy of stereotaxic targeting. Typically, 1–2 adjustments of needle depth were required to accurately infuse the brain region of interest, but medio-lateral and rostral-caudal trajectories were in nearly all cases accurate without requiring needle withdrawal and repositioning.

With positioning of the infusion needle in the entorhinal cortex at a depth of 1 mm from the cortical surface, infusion of the AAV2-BDNF/gadoteridol solution resulted in vector spread in cortical layers I–II over a rostral-to-caudal distance of 5–8 mm (green arrows in Fig. 3e, f). Occasionally, the tip of the infusion needle appeared to exit the ventral surface of the brain with resulting gadoteridol spread in the subarachnoid space; in these cases, the MRI tracer signal rapidly dissipated (within 10 min). When infusions were located intraparenchymally,
gadoteridol signal was persistently detectable over at least 30 min on MRI.

**Correlation of gadoteridol diffusion with BDNF transduction**

Anatomical examination of infused brains using BDNF immunolabeling demonstrated that vector spread assessed by gadoteridol on MRI scans during infusions closely matched in vivo BDNF gene expression (Fig. 3). Thus, gadoteridol spread at the time of vector infusion accurately reflected vector spread on histological examination.

**AAV2 primarily infects neurons of the entorhinal cortex**

Quantification of BDNF or green fluorescent protein (GFP) co-labeling with the neuronal marker NeuN indicated that AAV2 primarily infected neurons in the entorhinal cortex. Among the subjects that received AAV2-GFP, 88.2 ± 3.8% of cells expressing GFP were neurons, as assessed by double labeling with NeuN. Among BDNF-labeled cells, 85.9 ± 3.5% were co-labeled with NeuN (Fig. 4). As expected, cell transduction in white matter regions such as the angular bundle was low due to the absence of neurons in these regions.

**Entorhinal cortex BDNF expression correlates with vector infusion volume**

The volume of vector distribution of BDNF and GFP in the entorhinal cortex was measured in BDNF- and GFP-immunolabeled sections (Fig. 5). The volume of infused vector correlated significantly with the volume of transduced entorhinal cortex ($r(24) = 0.73$, $p < 0.0001$; Fig. 5d). Overall, across all animals with accurate vector targeting to the entorhinal cortex, the proportionate volume of transduced entorhinal cortex was 59.9 ± 6.7%. The total volume of vector infused among these subjects ranged from 15 to 184 µl per entorhinal cortex, spread over 1–3 infusions sites. Subjects with the greatest volume of BDNF expression in the entorhinal cortex generally received the highest number of infusions, reliably exhibiting >50% transduction of the entorhinal cortex with BDNF. A significant correlation also existed between the volume of the infused vector and the number of neurons expressing BDNF in the entorhinal cortex ($r(22) = 0.82$, $p < 0.0001$; Fig. 5e). While the total volume of vector infusion was an important consideration in maximizing the volume of entorhinal cortex transduction, accurate positioning of the infusion needle to a depth of approximately 1 mm from the ventral surface of the entorhinal cortex most consistently assured distribution within the target region.
BDNF trafficking to hippocampus

AAV2-BDNF vector infusion into the entorhinal cortex has previously been reported to result in anterograde trafficking of BDNF protein into the hippocampus [11, 12]. We also found this to be the case in the present study (Fig. 6a–d). Even relatively small volumes of BDNF transduction of the entorhinal cortex (e.g., 15 µl), when accurately targeted, resulted in widespread increases in BDNF labeling in the hippocampal dentate gyrus.

Discussion

BDNF gene delivery to the entorhinal cortex offers the potential to slow the degeneration and death, and stimulate the function, of cortical neurons that are affected in AD [8, 11, 12]. Findings of the present study indicate that the ability to accurately target this deep brain structure is substantially improved using real-time MRI targeting and co-infusion of gadoteridol. In previous experiments, we targeted vector injections into the non-human primate entorhinal cortex using stereotaxic coordinates only, without MRI guidance; these efforts resulted in accurate vector delivery into the entorhinal cortex in less than 50% of sites (data now shown). Injections were often off-target, located more frequently in the angular gyrus (subcortical white matter) and resulted in vector loss through white matter tracks with little transduction of gray matter. Using methods described in this study, we accurately target the entorhinal cortex in more than 95% of the monkeys, and can distribute vector over at least 50% of the volume of the target. These methods are safe and well-tolerated, and to date there have been no peri-operative complications after infusing a total of 18 monkeys.

Consistent with infusions of vector into other brain regions [21, 25, 35, 36], the volume of entorhinal cortex transduction with AAV2-BDNF correlated with the volume of vector infusion when infusions were accurately targeted into the entorhinal cortex. However, when the infusion needle tip was located in subcortical white matter, the vector rapidly diffused through white matter and did not efficiently transduce the entorhinal cortex. In this small gray matter region, it appears that the accuracy of needle placement is the most important consideration in effectively distributing AAV2-BDNF. Without real-time imaging and gadoteridol co-infusion, the entorhinal cortex was not consistently engaged in non-human primates, and likely would not be in a human clinical trial. Indeed, preliminary observations from our recent experience targeting another small brain region in AD patients with NGF gene delivery, the Nucleus Basalis of Meynert, showed mis-targeting of several injections, despite the fact that the trial used state-of-the-art stereotaxic methods and experienced neurosurgeons (clinicaltrials.gov). These observations indicate that the development of more accurate, real-time MRI-guided methods for gene delivery to smaller brain targets will be important for advancing future programs to human trials.

An important observation in this study was that BDNF is consistently trafficked into the hippocampus when AAV2-BDNF is accurately delivered to the entorhinal cortex. BDNF transport to the hippocampus could extend the distribution of BDNF in the AD brain, thereby accessing the brain regions that are affected the earliest and
most extensively in AD [11, 12]. By the time that AD is first diagnosed in humans, up to 50% of neurons in the entorhinal cortex have already degenerated [7]. Notably, pathology in the AD brain typically spreads from the entorhinal cortex to more distant brain regions; indeed recent findings suggest that spread of toxic protein species from the entorhinal cortex may propagate AD pathology to other brain regions [4, 5, 37, 38]. If this is true, then early reduction or arrest of cell degeneration in the entorhinal cortex and hippocampus could reduce the progression of AD. Targeting the entorhinal cortex and hippocampus with BDNF could therefore extend neuroprotection to broader cortical regions. And as the ability to detect AD risk at pre-symptomatic stages of the disease advances [39, 40], there is potential to begin intervention with BDNF in patients at early time points, before cell loss is extensive.

Summary

MRI guidance with co-infusion of gadoteridol permits accurate delivery of AAV2-BDNF to the non-human primate entorhinal cortex. The establishment of these methods enables potentially more effective clinical translation of this approach in an effort to prevent neuronal loss and stimulate neuronal function in AD.

Methods

Subjects

The subjects were five adult cynomologus macaques (Macaca fascicularis; 5.9–10.0 kg; four males, one female; age range 3–14 years) and 13 adult rhesus macaques (Macaca mulatta; 6.0–18.7 kg; nine males, four females; age range 5–21 years). The animals were housed in a temperature-controlled environment with 12-hour light/dark cycle. All subjects were seronegative for the presence of anti-AAV antibodies with antibody titers of <1:100, using previously described protocols [41]. All procedures were carried out in accordance with the Institutional Animal Care and USE Committee at UCSF and UC Davis.

Vector production and preparation

AAV2-BDNF vector was produced by UNC Vector Core (University of North Carolina) The vector genome consists of the human BDNF cDNA with a CAG promoter consisting of human cytomegalovirus (CMV) enhancer, chicken β-actin promoter and splice donor, intron, a rabbit β-globin splice acceptor. The vector is similarly designed to AAV2 vector used in Phase 1 and 2 gene therapy trials [14, 42, 43]. Briefly, vector particles were prepared by transient transfection of plasmid DNA into 293 cells and purified by CsCl2 centrifugation, FPLC, and sterile filtration. AAV2-BDNF vector
was delivered at a titer of $3 \times 10^{12}$ vg/ml and aliquotted into 100 µl volumes. For infusions, AAV2-BDNF was infused at a concentration of $3 \times 10^{11}$ vg/ml. The MR contrast agent gadoteridol (Prohance, Bracco Diagnostic, Princeton, NJ) was mixed into the vector at a final concentration of 1 mM. A subset of subjects ($N = 9$) also received AAV2-GFP at $0.03 \times 10^{12}$ vg/ml titer to confirm the spread of the viral vector in the transduction of cells.

**Surgical exposure**

After induction of anesthesia, the animal’s head was placed in a stereotactic frame and flexed in a prone position. The head was shaved and cleaned using Nolvasan solution and alcohol. A sterile field was created and a midline incision performed through the skin, muscle, and fascia by electrocautery (Surgistat Electrosurgery, Valleylab Inc., Boulder, CO). Gentle retraction of fascia and muscle allowed for cranial exposure over cortical entry sites. Small burr holes were performed according to stereotactic coordinates to expose the dura over each of the intended infusion sites. The infusion system included (i) a “ball-joint” style array (Hayes Manufacturing Services Inc., USA) that was secured to the skull by titanium screws over the craniotomies, and (ii) a custom-designed cannula (Richardson et al. [24, 26]). The custom-designed, ceramic, fused silica reflux-resistant cannula [44] consists of an 8–25-cm ceramic section (1.68 mm outer diameter (OD)) in the main portion of the shaft, and an 18-mm fused silica section that tapers down to 0.7 mm OD. The final 3-mm section is a fine fused silica tip (0.36 mm OD). Briefly, the cannula is connected to a loading line containing the infusate, and flow is regulated with a 1-ml syringe mounted onto an MRI-compatible infusion pump. The target is selected and optimal trajectory is established using neuronavigation software on baseline MRI images of the animal. Then, distance from the target to the top of the guide-stem is determined in silico, and a depth-stop is secured at the insertion distance in the cannula. After the optimal infusion parameters are determined, the cannula is manually inserted through the guiding-stem of the array to the target.

**MRI-guided infusion procedure**

We used a 3-Tesla Siemens Magnetom Avanto scanner (Siemens Medical Solutions, Erlangen, Germany) with Siemens resident software. Vector infusion procedures were done using three types of scanning protocols that were varied throughout the gene delivery procedure: a T1 protocol to optimize the visualization of brain structures for the purpose of needle targeting, and modified T2 protocol to obtain a rapid scan to assess vector spread, and an MP-
RAGE protocol to optimize the visualization of white matter structure and vector spread (repetition time: 2110 ms; echo time: 3.6 ms; flip angle: 15°; number of excitations: 1 (repeated three times); matrix: 240 × 240; field of view: 240 × 240 × 240).

The animals were sedated with an intramuscular injection of ketamine (10 mg/kg IM) and medetomidine (0.015 mg/kg IM), intubated, and a venous line established with a 22–24-gauge catheter positioned in the cephalic or saphenous vein to deliver isotonic fluids at a rate of 5–10 ml/kg/h. Isoflurane inhalation anesthesia (Aerrane, Omeda PPD Inc., Liberty, NJ) was delivered at 1–3% to maintain a stable plane of anesthesia. Then, after placement into an MRI-compatible stereotaxic frame in a supine position, two burr holes were placed for implantation of ball-joint arrays that consist of a base (attached to the skull) and a guide tube array (cylinder with three holes) [45]. The monkeys were then transferred to the MRI scanner suite. The infusion needle consisted of a ceramic silica reflux-resistant cannula with a 1-mm step at the distal end to prevent vector reflux up the cannula (MRI Intervention, Irvine). [25] Then a 36-inch high-pressure intravenous tubing connected the infusion needle to a 1-ml syringe pump (Medfusion 3500 syringe pump, Medfusion, St Paul, MN). Prior to loading into the infusion system, the vector was adjusted to a final concentration of 3.0 × 10^{11} vg/ml. In nine subjects, one-tenth of the vector infusate volume consisted of AAV2-GFP (3 × 10^{11} vp/ml) and 90% of the vector consisted of AAV2-BDNF (3 × 10^{11} vg/ml); these monkeys enabled analysis of the type of cells in the brain that were transduced by the virus. In initial subjects, the infusion needle was placed into the skull-based stereotaxic frame and advanced into the brain to a point calculated to be located in the mid-striatum; the accuracy of the needle trajectory and depth were then confirmed with a T2 scan. Because none of these mid-trajectory scans required correction of needle trajectory, all subsequent subjects underwent lowering of the infusion needle into the entorhinal cortex itself, stopping at a point calculated on initial MRI scans to be located 1 mm dorsal to the intended target region. Then, a T1, MP-RAGE and T2 weighted set of images were obtained. Based on these images, we then advanced the infusion needle to the distance required to reach a point within the entorhinal cortex that was located 1 mm from the ventral brain surface (Fig. 2).

The monkeys received 1–3 infusion sites into the entorhinal cortex per side of the brain. For a single infusion per side, the injection was placed approximately at the mid-point of the antero-posterior length of the hippocampus. For entorhinal cortex that received 2–3 infusions, attempts were made to spread the vector through the majority of the volume of the entorhinal cortex. For this study, 34 entorhinal cortices were infused with AAV2-BDNF (3 × 10^{11} vg/ml): 18 received a single infusion site per side of the brain, nine received two infusions, and seven receiving three infusions.

At the point that infusion needles were going to penetrate the brain, infusions pumps were turned on at a rate of 3 µl/min to maintain positive pressure and prevent needle blockade as the needle was advanced through the brain to the target. Once the final target was confirmed on MRI, the infusion rate was adjusted ramping from 1 up to 3 µl/min to achieve vector spread through the entorhinal cortex region located in the 1-mm-thick MRI slice containing the infusion needle. Rather than infuse a pre-set volume of vector, we continued infusions until the target region of interest (about 5 mm of the rostral-cadual extent of the entorhinal cortex) was covered by gadoteridol. Scans were continuously obtained through the infusion procedure, as previously described [21, 25]. The range of vector volume infused per site was 15–160 µl. Vital signs were monitored continuously during the surgery.

After completion of infusions, the subjects were returned to the surgical suite for removal of the skull-based stereotaxic frame. Then, the animals received an intramuscular injection of NSAID (Meloxicam) and buprenorphine (Buprenex) the day after the convection-enhanced delivery (CED) infusion as part of the post-procedural analgesia management. Once the animal returned to its cage, it was evaluated twice daily for 5 days by veterinary staff. Detailed, standardized forms were completed for each animal that included evaluations of the surgical-site integrity, edema, infection, balance, locomotion, attitude, food intake, and fecal and urine output. No abnormalities or signs of discomfort were reported.

**Histology**

The subjects were euthanized 1–6 months following MRI-guided infusions. The subjects were anesthetized as described previously using an intravenous overdose of sodium pentobarbital solution (B-euthanasia solution, 390 mg/ml). Death was confirmed by loss of heartbeat, respiration, pupil reflex, and/or toe pinch reflex. Then, the animals were transcardially perfused with cold 0.9% phosphate-buffered saline (PBS) followed by 4% paraformaldehyde (PFA). Brains were harvested and placed in a 10% glycerol solution for one night then transferred to 20% formaldehyde (PFA). Brains were harvested and placed in a 10% glycerol solution for one night then transferred to 20% glycerol. Histology was performed at UCSD. The brain was sectioned into 3 blocks, with the most caudal block containing the entorhinal cortex and hippocampus. Blocks were frozen in 99% isopentane and stored at −80 °C until sectioning. Sectioning was performed on a sliding microtone set at 40 µm thickness and each section was placed in 96-well polyethylene plates containing cryoprotectant. The tissue was stored at −20 °C.
Nissl staining and immunohistochemistry

A series of 1-in-12 sections were processed for Nissl staining using standard protocols. Another series of 1-in-24 sections were used for light level immunolabeling of BDNF using antigen retrieval method to enhance labeling. Antigen retrieval procedure involved sections in 0.01 M Tris-HCL (pH 9.0, at 80 °C) for 50 min and post-fixation in 2% PFA:0.2% para-benzoquinone for 5 min. The sections were incubated in primary rabbit anti-BDNF antibody (Chicago Proteintech; made for Tuszynski laboratory) at 1:2000 dilution for 4 nights at 4 °C. The sections were then incubated in secondary antibody (donkey anti-rabbit biotin, Proteintech; made for Tuszynski laboratory) at 1:2000, and were subsequently developed in 3,3′-diaminobenzidine. Additional series of 1-in-24 sections were also processed for fluorescent labeling using rabbit anti-BDNF antibody (1:1500, Chicago Proteintech), mouse anti-NeuN (1:2000, clone 1B7, Abcam; AB104224), and chicken anti-GFAP (1:500, Aves Lab; Cat# GFAP) for 4 nights and developed with Alexa Fluor secondary antibodies (1:200, Jackson ImmunoResearch Laboratories; Donkey Anti-Rabbit Alexa594 #711-585-152; Donkey Anti-Mouse #715-605-150; Donkey Anti-Chicken Alex 647 #703-605-152) and 1:1000 DAPI (Sigma D9542). Sections were mounted onto gelled slides and coverslip using Fluoromount-G (Southern Biotech).

AAV2-BDNF and AAV2-GFP targeting of neurons

Infusion of AAV2-BDNF and AAV2-GFP resulted in increased expression of the construct in cells at the infusion site. To determine the percentage of cells with elevated BDNF or GFP in neurons, the sections were tripled labeled for BDNF, GFP, and NeuN. Quantification was performed at individual infusion sites with selected samples taken across all layers of entorhinal cortex, including the angular bundle (white matter adjacent to entorhinal cortex). The percentage of cells co-labeled for BDNF or GFP with the neuronal marker NeuN was calculated.

Distribution of vector expression in entorhinal cortex

To determine the spread of the vector at the entorhinal cortex infusion sites, BDNF-immunolabeled cells were mapped using using Stereoinvestigator (Microbrightfield Bioscience). The sections labeled for BDNF at both fluorescence and light levels were used to enhance accuracy. Regions were sampled at section intervals of 1-in-12 to 1-in-48 sections. For each section, the entorhinal cortex was outlined based on anatomical features (e.g., rhinal fissure) and cytoarchitectural structures of the entorhinal cortex as viewed with NeuN labeling or adjacent Nissl-stained sections [46]. A total of 25 entorhinal cortex infusion sites were mapped for the distribution of the BDNF-immunolabeled cells and over 100,000 individual cells were mapped. Each BDNF cell was marked as neuronal or non-neuronal based on NeuN labeling.

The StereoInvestigator software provides the X-Y location of the cells. Using a protocol developed by A. Nagahara, Excel (Microsoft) templates were used to map the area of elevated BDNF expression. Briefly, using 300-µm bins for both y-axis and x-axis (e.g., 0–300, 301–600), the lowest and highest values were used as the border for each bin, and the area of BDNF expression was calculated in each anatomical section. To confirm this analysis, a Matlab program was written (I. Ivasyk) that utilized the BDNF location data to outline and measure the area of BDNF expression in each anatomical section. Based on these analyses, the total volume of BDNF protein expression was calculated by multiplying area per section by the sampling frequency of 1-in-12 sections and the thickness of each section. The estimated number of neurons that were labeled for BDNF cells was also quantified in 1-in-12 sections, with total neuron numbers estimated based on section sampling frequency (1-in-12). The volume of the tissue expressing BDNF was correlated to BDNF-expressing cell numbers.

BDNF elevation in entorhinal cortex and hippocampus

BDNF protein can be trafficked anterogradely through axonal transport from neurons in the entorhinal cortex to the hippocampus [12], providing a potential means of distributing BDNF throughout entorhinal cortex and into hippocampus following gene delivery to the entorhinal cortex [11, 12]. Previously, we reported that co-infusion of AAV2-GFP with AAV2-BDNF into the entorhinal cortex of rhesus macaques did not result in anterograde transport of the AAV2-GFP vector itself into the hippocampus [11], indicating that all BDNF protein that is present in the hippocampus results from anterograde transport of the protein, and not the AAV2-BDNF vector. To examine the extent of BDNF distribution into the hippocampus, we quantified regions of BDNF immunoreactivity in the hippocampal dentate gyrus 1-in-24 sections, which were scanned with a 2× objective lens on a Keyence (BZ-X700) microscope. The outer molecular layer of dentate gyrus was outlined in Adobe Photoshop software. Threshold analysis was used to determine the area with elevated BDNF levels in the entorhinal cortex and hippocampus. The threshold was based on the BDNF immunolabeling in control cortical brain regions (parietal or temporal cortex). The threshold was calculated from control cortical sample (15,000 pixels) and set at three times the standard deviation.
above the mean value. A standard threshold value was not used due to the variation of BDNF immunolabeling from subject to subject. Images were imported into ImageJ software and the percent of the region above the threshold value was calculated. Similar measures of fiber density were made in a series of 1-in-48 sections through the full rostral-to-caudal extent of the hippocampus.

**Statistical analyses**

Pearson correlational analyses were performed between the volume of AAV2-BDNF infused and the volume of tissue with BDNF-labeled neurons or the estimated number of BDNF-labeled neurons (JMP software from SAS). The sample size of the subjects for this study (N = 18) was based on a power analysis using a large effect size for correlational analyses (0.50), a power of 0.85, and the assumption of 90% accuracy of targeting (inclusion criteria). Only infusion sites that accurately targeted the entorhinal cortex were included for these analyses. Since group differences were not examined, randomization was not used in the present study. The experimenters were blinded for data collection. The Pearson correlational analysis was determined to be the appropriate analyses that meet the basic assumptions of this statistical test. Since there are no group comparisons, variance data are not presented.

**Acknowledgements**

We thank Megan Orr, Yuri Guan, An Hoang, Terri Grider, Adrian Kells, and Armin Blesch for their technical assistance.

**Funding**

This work was supported by the NIH (AG10435, AG043416), the Veterans Administration, and the Alzheimer’s Association (Zenith Award).

**Compliance with ethical standards**

**Conflict of interest**

The authors declare that they have no conflict of interest.
24. Richardson RM, Kells AP, Rosenbluth KH, Salegio EA, Fiandaca MS, Larson PS, et al. Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson’s disease. Mol Ther. 2011;19:1048–57.
25. San Sebastian W, Kells AP, Bringas J, Samaranch L, Hadaczek P, Ciesielksa A, et al. Safety and tolerability of MRI-guided infusion of AAV2-hAADC into the mid-brain of non-human primate. Mol Ther Methods Clin Dev. 2014;3:14049.
26. Richardson RM, Kells AP, Martin AJ, Larson PS, Starr PA, Piferi PG, et al. Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in non-human primate brain. Stereotact Funct Neurosurg. 2011;89:141–51.
27. Insausti R, Amaral DG, Cowan WM. The entorhinal cortex of the monkey: II. Cortical afferents. J Comp Neurol. 1987;264:356–95.
28. Witter MP, Van Hoesen GW, Amaral DG. Topographical organization of the entorhinal projection to the dentate gyrus of the monkey. J Neurosci. 1989;9:216–28.
29. Witter MP, Amaral DG. Entorhinal cortex of the monkey: V. Projections to the dentate gyrus, hippocampus, and subicular complex. J Comp Neurol. 1991;307:437–59.
30. Amaral DG. Emerging principles of intrinsic hippocampal organization. Curr Opin Neurobiol. 1993;3:225–9.
31. Lavenex P, Amaral DG. Hippocampal-neocortical interaction: a hierarchy of associativity. Hippocampus. 2000;10:420–30.
32. Kirkby DL, Higgins GA. Characterization of perforant path lesions in rodent models of memory and attention. Eur J Neurosci. 1998;10:823–38.
33. Myhrer T, Naevdal GA. The temporal-hippocampal region and retention: the role of temporo-entorhinal connections in rats. Scand J Psychol. 1989;30:72–80.
34. Paxinos G, Huang XF, Toga AW. The Rhesus monkey brain in stereotaxic coordinates. Academic Press; San Diego, 1989.
35. Salegio EA, Kells AP, Richardson RM, Hadaczek P, Forsayeth J, Bringas J, et al. Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders. Hum Gene Ther. 2010;21:1093–103.
36. Gimener F, Krauze MT, Valles F, Hadaczek P, Bringas J, Sharma N. et al. Image-guided convection-enhanced delivery of GDNF protein into monkey putamen. Neuroimage. 2011;54 Suppl 1: S189–95.
37. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, et al. Trans-synaptic spread of tau pathology in vivo. PLoS ONE. 2012;7:E31302.
38. Takeda S, Wegmann S, Cho H, DeVos SL, Commins C, Roe AD, et al. Neuronal uptake and propagation of a rare phosphorylated high-molecular-weight tau derived from Alzheimer’s disease brain. Nat Commun. 2015;6:8490.
39. Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673–84.
40. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andreu S. et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292–323.
41. Bevan AK, Duque S, Foust KD, Morales PR, Braun L, Schmelzer L, et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther. 2011;19:1971–80.
42. Arvanitakis Z, Tuszynski MH, Bakay R, Arends D, Potkin S, Bartus R, et al. Interim data from a phase 1 clinical trial of AAV-NGF (CERE-110) gene delivery in Alzheimers disease. Abstr Am Acad Neurol. 2007; p05.071.
43. Rafii MS, Baumann TL, Bakay RA, Ostrove JM, Siffert J, Fleisher AS. et al. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer’s disease. Alzheimers Dement. 2014;10:571–81.
44. Fiandaca MS, Forsayeth JR, Dickinson PJ, Bankiewicz KS. Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 2008; 5(1): 123–7.
45. Salegio EA, Bringas J, Bankiewicz KS. MRI-guided delivery of viral vectors. Methods Mol Biol. 2016;1382:217–30.
46. Amaral DG, Insausti R, Cowan WM. The entorhinal cortex of the monkey: I. Cytoarchitectonic organization. J Comp Neurol. 1987;264:326–55.